当前位置: 首页 >> 检索结果
381. Factors limiting participation in arthritis self-management programmes: an exploration of barriers and patient preferences within a randomized controlled trial.
作者: Ilana N Ackerman.;Rachelle Buchbinder.;Richard H Osborne.
来源: Rheumatology (Oxford). 2013年52卷3期472-9页
To improve understanding of barriers to participation in community-based arthritis self-management programmes and patient preferences for self-management education.
382. Postgraduate education to increase adherence to a Dutch physiotherapy practice guideline for hip and knee OA: a randomized controlled trial.
作者: Wilfred F Peter.;Philip J van der Wees.;John Verhoef.;Zuzana de Jong.;Leti van Bodegom-Vos.;Wim K H A Hilberdink.;Marta Fiocco.;Thea P M Vliet Vlieland.
来源: Rheumatology (Oxford). 2013年52卷2期368-75页
To compare the effectiveness of two educational courses aiming to improve adherence to recommendations in a Dutch physiotherapy practice guideline for hip and knee OA.
383. Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE).
作者: Désirée van der Heijde.;Jürgen Braun.;Atul Deodhar.;Robert D Inman.;Stephen Xu.;Michael E Mack.;Benjamin Hsu.
来源: Rheumatology (Oxford). 2013年52卷2期321-5页
To compare the abilities of three enthesitis indices to detect improvement in entheseal tenderness with the TNF antagonist golimumab in AS.
384. A randomized, double-blind, placebo-controlled trial of low-dose oral prednisolone for treating painful hand osteoarthritis.
作者: Claire Y J Wenham.;Elizabeth M A Hensor.;Andrew J Grainger.;Richard Hodgson.;Sharon Balamoody.;Caroline J Doré.;Paul Emery.;Philip G Conaghan.
来源: Rheumatology (Oxford). 2012年51卷12期2286-94页
Anti-inflammatory therapies are effective analgesics for OA. This study determined whether low-dose oral prednisolone (PNL) was an effective analgesic for hand OA.
385. Large-joint damage in patients with early rheumatoid arthritis and its association with treatment strategy and damage of the small joints.
作者: Linda Dirven.;Marianne van den Broek.;Herman M Kroon.;Bernard A M Grillet.;K Huub Han.;Pit J S M Kerstens.;Tom W J Huizinga.;Willem F Lems.;Cornelia F Allaart.
来源: Rheumatology (Oxford). 2012年51卷12期2262-8页
To determine the prevalence of large-joint damage and the association with small-joint damage in patients with RA after 8 years of low DAS (≤2.4)-targeted treatment with different treatment strategies.
386. A randomized controlled trial of a cognitive behavioural patient education intervention vs a traditional information leaflet to address the cardiovascular aspects of rheumatoid disease.
作者: Holly John.;Elizabeth D Hale.;Gareth J Treharne.;George D Kitas.;Douglas Carroll.
来源: Rheumatology (Oxford). 2013年52卷1期81-90页
Cardiovascular disease (CVD) is responsible for 50% of the excess mortality for patients with RA. This study aimed to evaluate a novel 8-week cognitive behavioural patient education intervention designed to effect behavioural change with regard to modifiable CVD risk factors in people with RA.
387. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study.
作者: Michael E Weinblatt.;Roy Fleischmann.;Tom W J Huizinga.;Paul Emery.;Janet Pope.;Elena M Massarotti.;Ronald F van Vollenhoven.;Jürgen Wollenhaupt.;Clifton O Bingham.;Ben Duncan.;Niti Goel.;Owen R Davies.;Maxime Dougados.
来源: Rheumatology (Oxford). 2012年51卷12期2204-14页
To investigate the efficacy and safety of certolizumab pegol (CZP) in a broad population of patients with active RA.
388. TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients.
作者: Ivan Leonardo Avelino França.;Ana Cristina Medeiros Ribeiro.;Nádia Emi Aikawa.;Carla Gonçalves Schain Saad.;Julio Cesar Bertacine Moraes.;Cláudia Goldstein-Schainberg.;Ieda Maria Magalhães Laurindo.;Alexander Roberto Precioso.;Maria Akiko Ishida.;Ana Marli Christovam Sartori.;Clovis Artur Silva.;Eloisa Bonfa.
来源: Rheumatology (Oxford). 2012年51卷11期2091-8页
To evaluate the immunogenicity of the anti-influenza A H1N1/2009 vaccine in RA and spondyloarthritis (SpA) patients receiving distinct classes of anti-TNF agents compared with patients receiving DMARDs and healthy controls.
389. The early psoriatic arthritis screening questionnaire: a simple and fast method for the identification of arthritis in patients with psoriasis.
作者: Ilaria Tinazzi.;Silvano Adami.;Elisabetta Maria Zanolin.;Cristian Caimmi.;Silvia Confente.;Giampiero Girolomoni.;Paolo Gisondi.;Domenico Biasi.;Dennis McGonagle.
来源: Rheumatology (Oxford). 2012年51卷11期2058-63页
Dermatologists usually see patients with psoriasis before arthritis develops, making them well placed to diagnose early PsA (ePsA). This study aimed to develop a rapid and robust screening questionnaire for predicting PsA in patients with psoriasis referred to a specialized joint dermatology-rheumatology combined clinic.
390. Worst-case future scenarios of patients with rheumatoid arthritis: a cross-sectional study.
作者: Laurien Buitinga.;Louise M A Braakman-Jansen.;Erik Taal.;Mart A F J van de Laar.
来源: Rheumatology (Oxford). 2012年51卷11期2027-33页
The time trade-off is a health-related quality of life instrument that measures valuations for health states (utilities) by asking patients to value their health state anchored on a scale between death (0) and perfect health (1). Dying earlier is not perceived as a realistic worst-case consequence of the disease by RA patients. Of the previous focus groups study on RA patients, five worst-case future scenarios emerged. The aim of this study was to examine which potential worst-case scenario was the most appropriate for RA patients to use in utility calculation.
391. Comparison of joint destruction between standard- and low-dose etanercept in rheumatoid arthritis from the Prevention of Cartilage Destruction by Etanercept (PRECEPT) study.
作者: Masahiro Tada.;Tatsuya Koike.;Tadashi Okano.;Yuko Sugioka.;Shigeyuki Wakitani.;Kenzo Fukushima.;Akira Sakawa.;Kazunori Uehara.;Kentaro Inui.;Hiroaki Nakamura.
来源: Rheumatology (Oxford). 2012年51卷12期2164-9页
To evaluate the prevention of joint destruction and clinical efficacy of low-dose etanercept (ETN) (25 mg/week) compared with standard-dose ETN (50 mg/week) in RA.
392. Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in patients treated with etanercept or sulphasalazine in the ASCEND trial.
作者: Désirée van der Heijde.;Jürgen Braun.;Maxime Dougados.;Joachim Sieper.;Ronald Pedersen.;Annette Szumski.;Andrew S Koenig.
来源: Rheumatology (Oxford). 2012年51卷10期1894-905页
The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a new composite clinical tool combining subjective and objective measures. Using data from the randomized double-blind Ankylosing Spondylitis Study Comparing Enbrel with Sulfasalazine Dosed Weekly (ASCEND) trial, we tested ASDAS validity and assessed its capacity to discriminate between treatment effects and change-from-baseline improvements.
393. Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study.
作者: Vibeke Strand.;Gerd R Burmester.;Sarika Ogale.;Jenny Devenport.;Ani John.;Paul Emery.
来源: Rheumatology (Oxford). 2012年51卷10期1860-9页
To investigate the effect of tocilizumab on patient-reported outcomes (PROs) in RA patients with inadequate responses to TNF inhibitors (TNFis).
394. Continuous efficacy of etanercept in severe and advanced ankylosing spondylitis: results from a 12-week open-label extension of the SPINE study.
作者: Maxime Dougados.;Jurgen Braun.;Sandor Szanto.;Bernard Combe.;Pal Geher.;Veronique Leblanc.;Isabelle Logeart.
来源: Rheumatology (Oxford). 2012年51卷9期1687-96页
To evaluate the longer-term efficacy of etanercept in patients with severe and advanced active AS.
395. Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial.
作者: Edward C Keystone.;Bernard Combe.;Josef Smolen.;Vibeke Strand.;Niti Goel.;Ronald van Vollenhoven.;Philip Mease.;Robert Landewé.;Roy Fleischmann.;Kristel Luijtens.;Désirée van der Heijde.
来源: Rheumatology (Oxford). 2012年51卷9期1628-38页
To evaluate the safety and efficacy of 2-year administration of certolizumab pegol (CZP) + MTX in patients with active RA.
396. Comparison of surgical decompression and local steroid injection in the treatment of carpal tunnel syndrome: 2-year clinical results from a randomized trial.
作者: Domingo Ly-Pen.;José-Luis Andréu.;Isabel Millán.;Gema de Blas.;Alberto Sánchez-Olaso.
来源: Rheumatology (Oxford). 2012年51卷8期1447-54页
To compare the efficacy of surgical decompression vs local steroid injection in the treatment of idiopathic CTS.
397. Treatment decisions and related costs differ significantly depending on the choice of a disease activity index in RA, according to 1987 and 2010 classification criteria.
作者: Pascal H P de Jong.;Johanna M W Hazes.;Derkjen van Zeben.;Peter A van der Lubbe.;Mike H de Jager.;Peter B de Sonnaville.;Jolanda J Luime.;Angelique E A M Weel.
来源: Rheumatology (Oxford). 2012年51卷7期1269-77页
To evaluate the therapeutic and economic consequences of various disease activity indices (DAIs) in RA according to 1987 and 2010 criteria.
398. Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX.
作者: Ernest Choy.;Frank McKenna.;Jiri Vencovsky.;Robert Valente.;Niti Goel.;Brenda Vanlunen.;Owen Davies.;Hans-Detlev Stahl.;Rieke Alten.
来源: Rheumatology (Oxford). 2012年51卷7期1226-34页
Certolizumab pegol (CZP) is known to be effective as monotherapy at a dosage of 400 mg every 4 weeks in patients with active RA who have failed DMARDs. The aim of this study was to investigate every 4-week CZP in addition to continued MTX therapy in patients with an inadequate response to MTX alone.
399. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis.
作者: Gabrielle H Kingsley.;Anna Kowalczyk.;Helen Taylor.;Fowzia Ibrahim.;Jonathan C Packham.;Neil J McHugh.;Diarmuid M Mulherin.;George D Kitas.;Kuntal Chakravarty.;Brian D M Tom.;Aidan G O'Keeffe.;Peter J Maddison.;David L Scott.
来源: Rheumatology (Oxford). 2012年51卷8期1368-77页
MTX is widely used to treat synovitis in PsA without supporting trial evidence. The aim of our study was to test the value of MTX in the first large randomized placebo-controlled trial (RCT) in PsA.
400. Evaluation of Ankylosing Spondylitis Quality of Life questionnaire: responsiveness of a new patient-reported outcome measure.
作者: Jon C Packham.;Kelvin P Jordan.;Kirstie L Haywood.;Andrew M Garratt.;Emma L Healey.
来源: Rheumatology (Oxford). 2012年51卷4期707-14页
To determine the responsiveness and minimal important change (MIC) of Evaluation of Ankylosing Spondylitis Quality of Life (EASi-QoL), a reliable and valid patient-reported measure of AS-specific quality of life with four domains: physical function (PF), disease activity (DA), emotional well-being (EWB) and social participation (SP).
|